BRPI0417747A - uso de compostos orgánicos - Google Patents

uso de compostos orgánicos

Info

Publication number
BRPI0417747A
BRPI0417747A BRPI0417747-9A BRPI0417747A BRPI0417747A BR PI0417747 A BRPI0417747 A BR PI0417747A BR PI0417747 A BRPI0417747 A BR PI0417747A BR PI0417747 A BRPI0417747 A BR PI0417747A
Authority
BR
Brazil
Prior art keywords
organic compounds
pharmaceutically acceptable
pitavastatin
statin
medicament
Prior art date
Application number
BRPI0417747-9A
Other languages
English (en)
Inventor
Michele Bortolini
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0417747A publication Critical patent/BRPI0417747A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

"USO DE COMPOSTOS ORGáNICOS". A presente invenção refere-se ao uso de uma composição farmacêutica consistindo em estatina (especialmente fluvastatina ou pitavastatina) ou um sal farmaceuticamente aceitável da mesma e um veículo farmaceuticamente aceitável para a preparação de um medicamento para a prevenção ou tratamento da síndrome metabólica (ou síndrome X).
BRPI0417747-9A 2003-12-16 2004-12-15 uso de compostos orgánicos BRPI0417747A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52983103P 2003-12-16 2003-12-16
PCT/EP2004/014304 WO2005058310A2 (en) 2003-12-16 2004-12-15 Use of stating for the treatment of metabolic syndrome

Publications (1)

Publication Number Publication Date
BRPI0417747A true BRPI0417747A (pt) 2007-04-10

Family

ID=34700055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417747-9A BRPI0417747A (pt) 2003-12-16 2004-12-15 uso de compostos orgánicos

Country Status (11)

Country Link
US (1) US20070275996A1 (pt)
EP (1) EP1699452A2 (pt)
JP (1) JP2007513991A (pt)
KR (1) KR20060124634A (pt)
CN (1) CN1889948A (pt)
AU (1) AU2004298351A1 (pt)
BR (1) BRPI0417747A (pt)
CA (1) CA2546793A1 (pt)
MX (1) MXPA06006831A (pt)
RU (1) RU2006125512A (pt)
WO (1) WO2005058310A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527577A (ja) * 2006-02-24 2009-07-30 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム医薬組成物
PT2000137E (pt) * 2006-03-29 2016-02-17 Kowa Co Agente redutor de triglicerídeos e agente melhorador de hiperinsulinismo
EP1911441A3 (en) * 2006-10-11 2008-08-06 Lupin Limited Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents
IS8612A (is) * 2007-02-19 2008-08-20 Actavis Group Ptc Ehf. Stöðugar statínlyfjasamsetningar
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
FR2987270A1 (fr) * 2012-02-29 2013-08-30 Agronomique Inst Nat Rech Produit de combinaison pour le traitement du surpoids et/ou l'amelioration de la silhouette

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405793A1 (en) * 2000-04-12 2001-10-18 Novartis Ag Combination of organic compounds
AR039090A1 (es) * 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
HUP0300990A2 (hu) * 2003-04-15 2005-05-30 SynoSens Kutató és Fejlesztő Kft. Szinergista gyógyszer-kombináció a diabetesz megelőzésére vagy kezelésére
AU2004233691B2 (en) * 2003-04-28 2007-09-20 Sankyo Company, Limited Sugar intake-ability enhancer

Also Published As

Publication number Publication date
AU2004298351A1 (en) 2005-06-30
JP2007513991A (ja) 2007-05-31
WO2005058310A3 (en) 2005-08-25
RU2006125512A (ru) 2008-01-27
CN1889948A (zh) 2007-01-03
EP1699452A2 (en) 2006-09-13
MXPA06006831A (es) 2006-08-23
US20070275996A1 (en) 2007-11-29
CA2546793A1 (en) 2005-06-30
KR20060124634A (ko) 2006-12-05
WO2005058310A2 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
RS114004A (en) Modified 2' and 3'-nucleoside produgs for treating flaviridae infections
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
ITRM990338A0 (it) Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
BRPI0507497A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5
BR0315580A (pt) Derivados de metileno uréia
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
BR0010520A (pt) Novos compostos farmaceuticamente ativos
BR0210028A (pt) Agentes antibacterianos
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
SE9901573D0 (sv) New compounds
TR199900336T2 (xx) EAA antagonistleri olarak tetrahidrokinolin t�revleri.
BRPI0508079A (pt) composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c
TR200002969T2 (tr) Farmasötik bileşim.
BRPI0405657A (pt) Método para o tratamento de insuficiência cardìaca grave e medicamento para o mesmo
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
BRPI0514892A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0417747A (pt) uso de compostos orgánicos
RU2007149337A (ru) Новый способ лечения гиперлипидемии
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.